Blog
RSS FeedPosted by Michael Wonder on 16 Jul 2019
Ask whether a drug works before worrying about what it costs
16 July 2019 - Last week was supposed to be a turning point for drug price transparency. ...
Posted by Michael Wonder on 25 Jun 2019
Do cancer treatments have option value? Real‐world evidence from metastatic melanoma
24 June 2019 - A change in the expectations about future treatments may change the option value of a current ...
Posted by Michael Wonder on 24 Jun 2019
It’s Pioneer Institute vs. ICER: drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach
24 June 2019 - An influential Boston-based watchdog group uses a “one-size-fits-all” approach to judge a fair price for prescription ...
Posted by Michael Wonder on 20 Jun 2019
Novel approaches to value assessment within the cost-effectiveness framework
20 June 2019 - The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis of healthcare interventions ...
Posted by Michael Wonder on 20 Jun 2019
Drug pricing should reflect value, not recoupment of investment
20 June 2019 - The other day I was reading a piece on reframing the conversation on drug pricing. I ...
Posted by Michael Wonder on 18 Jun 2019
Zolgensma: a remarkable new treatment, an ICER analysis, and a poorly justified price
18 June 2019 - Defects in both sets of alleles in the coding region for the survival motor neuron 1 ...
Posted by Michael Wonder on 15 Jun 2019
New cost-effectiveness methods to determine value-based prices for potential cures: what are the options?
12 June 2019 - Evaluating different approaches to assessing the clinical effectiveness and value of potential cures will be essential to ...
Posted by Michael Wonder on 11 Jun 2019
Systematic literature review calls economic impact of switching to biosimilars "uncertain"
10 June 2019 - Biosimilar drugs are intended by their developers to provide a cost-saving alternative to brand-name biologics, and ...
Posted by Michael Wonder on 10 Jun 2019
The $2.1 million question: what are the medical, ethical implications of the world's priciest drug?
10 June 2019 - With last month’s FDA approval, Zolgensma became the world’s most expensive medication. ...
Posted by Michael Wonder on 05 Jun 2019
Paying for CAR-T therapy amidst limited health system resources
3 June 2019 - CAR-T is paving a new path toward achieving access and reimbursement within limited health-system resources. How do ...
Posted by Michael Wonder on 03 Jun 2019
Australians’ lives have a price – a ‘quality-adjusted life year’ worth about $50,000
3 June 2019 - How much is your life worth? What would you pay to keep it? More importantly, what would ...
Posted by Michael Wonder on 29 May 2019
Cost effectiveness analysis in the context of US commercial health insurance
29 May 2019 - Discussions of the cost effectiveness of medical services often are couched in the framework of a ...
Posted by Michael Wonder on 25 May 2019
ICER comments on the FDA approval of Zolgensma for the treatment of spinal muscular atrophy
24 May 2019 - ICER’s update reflects the gene therapy’s new clinical data and FDA label. ...
Posted by Michael Wonder on 22 May 2019
Extending VBP models into Medicaid drug purchasing: challenges and opportunities
22 May 2019 - Over the past decade, both public and private payers have increasingly sought to develop payment policies that ...
Posted by Michael Wonder on 21 May 2019
Official Information Act response: adrenaline auto-injector cost utility analysis
20 May 2019 - PHARMAC responds to a request for any cost utility analyses performed by PHARMAC in relation to ...